Precipio Terminates Sales Agreement with A.G.P.

Precipio Inc., a healthcare biotechnology company, has terminated its sales agreement with A.G.P. The company is focused on cancer diagnostics and develops diagnostic products, reagents, and services to improve accuracy and efficiency. Its technologies include HemeScreen and IV-Cell, which address diagnostic mistakes and improve testing processes. Precipio has laboratory and R&D facilities in Connecticut and Nebraska.

NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) — Precipio Inc., a healthcare biotechnology company specializing in cancer diagnostics, has terminated its At-The-Market (ATM) instrument with investment bank Alliance Global Partners (AGP). This move underscores the company's commitment to responsible capital management and its growing financial stability.

Precipio's CEO, Ilan Danieli, stated, "Our company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations and recent increases in our cash balance, we no longer need to rely on a tool like this for capital raises." This decision marks another step in the company's strategy to create shareholder value [1].

Precipio is dedicated to addressing the pervasive problem of cancer misdiagnoses by developing innovative diagnostic products and services. Their technologies, HemeScreen and IV-Cell, are designed to improve diagnostic accuracy and efficiency. HemeScreen tests for various mutations, while IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages, streamlining the testing process [2].

The company's laboratory and research and development (R&D) facilities are located in New Haven, Connecticut, and Omaha, Nebraska. Precipio's mission is to enhance diagnostic outcomes and reduce healthcare expenses by providing higher accuracy and improved laboratory workflows.

References:
[1] https://finance.yahoo.com/news/precipio-terminates-atm-140000076.html
[2] https://www.marketscreener.com/news/precipio-terminates-its-at-the-market-instrument-ce7c50d3d08af62d